AN ACT Relating to facilitating the prompt replacement of defective continuous glucose monitoring equipment;
Summary
HB1850 would require pharmacies in Washington that dispense continuous glucose monitoring (CGM) equipment to keep enough monitoring sensors on hand to provide a replacement sensor to a patient the same day when a device malfunctions or an emergency requires an additional sensor. For physical-location pharmacies, the replacement must be available the same day; for mail-order pharmacies, the bill requires prompt replacement, defined as mailing the sensor no later than the next business day, or as soon as practicable if next-day mailing is not possible.
The bill adds a new section to chapter 18.64 RCW, which governs pharmacies and pharmacists, and creates an operational requirement for pharmacies that dispense CGM devices. It is aimed at reducing gaps in diabetes monitoring by ensuring patients can quickly obtain backup sensors when their equipment fails or they need an extra sensor in an urgent situation. The measure does not appear to change insurance coverage or prescribing rules, but instead focuses on pharmacy inventory and fulfillment practices.
Impact
The bill would impose a new statutory duty on pharmacies that dispense continuous glucose monitoring equipment to maintain a sufficient inventory of sensors for replacement purposes. This would affect both brick-and-mortar and mail-order pharmacies, with different timing standards for each, and would likely require pharmacies to adjust stocking, ordering, and fulfillment procedures. The practical effect is to strengthen access to diabetes monitoring supplies and reduce interruptions in patient care when CGM equipment malfunctions or an emergency arises.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall sentiment appears supportive and straightforward. The bill’s purpose is framed as facilitating prompt replacement of defective equipment, suggesting a consumer- and patient-protection approach rather than a controversial policy change. No opposing arguments, amendments, or divided votes are reflected in the available record.
Contention
No specific points of contention are shown in the provided materials. Potential issues, if raised in discussion, would likely center on pharmacy compliance burdens, inventory costs, and the feasibility of maintaining sufficient sensor stock, especially for mail-order operations. However, the record provided does not identify any legislators, stakeholders, or committee members taking opposing positions.